Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016729 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
A Phase 1 study of Cancer and Acute Myeloid Leukemia, sponsored by Kartos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT02016729: Completed Phase 1 study of Cancer and Acute Myeloid Leukemia, sponsored by Kartos Therapeutics.
NCT02016729 is a Phase 1 study of Cancer and Acute Myeloid Leukemia that has completed, run by Kartos Therapeutics. The registered enrollment target is 36 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02016729, a Phase 1 study of Cancer and Acute Myeloid Leukemia, has completed, sponsored by Kartos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
Primary Outcome
To evaluate the safety and tolerability of AMG 232 by reviewing clinically significant or ≥ Grade 3 changes in safety laboratory tests, physical examinations, ECGs, or vitals signs in all subjects enrolled.
Conditions Studied
Interventions
- DRUG Trametinib
- DRUG AMG 232
Study Locations (5)
Alabama
- Research Site - Birmingham
New York
- Research Site - Buffalo
North Carolina
- Research Site - Charlotte
Utah
- Research Site - Salt Lake City
Washington
- Research Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-04-01 |
| Est. Completion | 2017-07-31 |
| Phase | Phase 1 |
What the finished NCT02016729 record still lists
NCT02016729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trametinib is the first listed.
NCT02016729 lists 5 locations in 5 states (Alabama, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02016729 about?
NCT02016729 is a clinical study titled "A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia". Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.
What is the current status of trial NCT02016729?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-04-01. Estimated completion is 2017-07-31.
What conditions does trial NCT02016729 study?
This clinical trial studies the following conditions: Cancer, Acute Myeloid Leukemia, Oncology, Oncology Patients, Advanced Malignancy.
What interventions are being tested in trial NCT02016729?
The interventions under investigation include: Trametinib (DRUG), AMG 232 (DRUG).
Who is sponsoring clinical trial NCT02016729?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02016729 being conducted?
This trial has 5 study locations across Alabama, New York, North Carolina, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02016729's enrollment target sits among peer trials
36 485th of 615 higher than 129 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI